Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension-Reference-Cited by-同舟云学术

Discovery of Riociguat (BAY 63-2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension

Published:2009-05-11 Issue:5 Volume:4 Page:853-865
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Mittendorf Joachim,Weigand Stefan,Alonso-Alija Cristina,Bischoff Erwin,Feurer Achim,Gerisch Michael,Kern Armin,Knorr Andreas,Lang Dieter,Muenter Klaus,Radtke Martin,Schirok Hartmut,Schlemmer Karl-Heinz,Stahl Elke,Straub Alexander,Wunder Frank,Stasch Johannes-Peter

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Reference77 articles.

1. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

2. Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The U.S. FDA approved cardiovascular drugs from 2011 to 2023: A medicinal chemistry perspective;European Journal of Medicinal Chemistry;2024-09

2. Identification of new multi-substituted 1H-pyrazolo[3,4-c]pyridin-7(6H)-ones as soluble guanylyl cyclase (sGC) stimulators with vasoprotective and anti-inflammatory activities;Bioorganic Chemistry;2024-03

3. CASE HISTORY: DISCOVERY AND DEVELOPMENT OF VERQUVO® (VERICIGUAT), A SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR FOR THE TREATMENT OF CHRONIC HEART FAILURE;Medicinal Chemistry Reviews;2023-11-16

4. A review: FDA-approved fluorine-containing small molecules from 2015 to 2022;European Journal of Medicinal Chemistry;2023-11

5. Development of a new synthetic route of the key intermediate of riociguat;Synthetic Communications;2023-08-29